What Has Been The Evolution of the Veterinary Autoimmune Disease Therapeutics Market in Recent Years?
The veterinary autoimmune disease therapeutics market has seen considerable growth due to a variety of factors.
• The veterinary autoimmune disease therapeutics market has grown steadily in recent years. It will rise from $3.25 billion in 2024 to $3.47 billion in 2025, with a CAGR of 6.8%.
The growth is driven by advances in immunology, increased pet ownership, improved diagnostic methods, the development of new drug classes, and greater awareness of pet health.
How Will the Veterinary Autoimmune Disease Therapeutics Market?
The veterinary autoimmune disease therapeutics market is expected to maintain its strong growth trajectory in upcoming years.
• The veterinary autoimmune disease therapeutics market is set to grow to $4.48 billion by 2029 with a CAGR of 6.6%.
This growth is fueled by advancements in biotechnology, higher investment in veterinary healthcare, the rising prevalence of autoimmune diseases in pets, the development of new treatments, and growing pet insurance adoption. Trends in the market include personalized medicine, the use of biologics, telemedicine integration, regenerative therapies, and a focus on holistic and integrative treatments.
Which Factors Are Boosting Growth In The Veterinary Autoimmune Disease Therapeutics Market?
The anticipated upsurge in the veterinary autoimmune disease therapeutics market is directly linked to the increase in funding for research in veterinary medicine. Veterinary medicine, focused on prevention, diagnosis, and treatment of health issues in animals, records this expansion in funding. This growth is tied to multiple factors such as the rise in zoonotic diseases, the boom in pet industry, advancements in animal health tech, agricultural needs, and efforts in preserving wildlife. The funding generated specifically for research in veterinary autoimmune disease is channeled into investigations on disease processes, diagnostic devices, and therapeutic alternatives that enhance the capacity of the vet medicine sector in effectively diagnosing and managing these diseases. In a notable instance, the National Institute of Food and Agriculture, a US-based agricultural department, disclosed, as per the August 2024 announcement, that it preferred the Veterinary Service Grants Program (VSGP) with NIFA for an investment of $3.2 million in rural food animal vet medicine in the fiscal year 2022 throughout the U.S. Hence, the growth in the veterinary autoimmune disease therapeutics market is attributable to the surge in funding for vet medicine research.
What Key Areas Define The Segmentation Of The Global Veterinary Autoimmune Disease Therapeutics Market?
The veterinary autoimmune disease therapeutics market covered in this report is segmented –
1) By Therapy Type: Corticosteroids, Azathioprine, Cyclosporine, Mycophenolate, Leflunomide, Cyclophosphamide, Levothyroxine, Folic Acid, Hydroxychloroquine, Chloroquine
2) By Animal Type: Companion Animals, Livestock Animals, Other Animals
3) By Disease: Hypothyroidism, Pemphigus Disease, Canine Lupus, Auto-Immune Hemolytic Anemia, Bullous Pemphigoid, Discoid Lupus Erythematosus (DLE), Immune-Related Arthritis, Other Diseases
4) By Distribution Channel: Veterinary Hospitals, Veterinary Clinics
Subsegments:
1) By Corticosteroids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Triamcinolone
2) By Azathioprine: Azathioprine Oral Tablets, Azathioprine Injectable Formulation
3) By Cyclosporine: Oral Cyclosporine (Atopica), Injectable Cyclosporine
4) By Mycophenolate: Mycophenolate Mofetil (Oral Form), Mycophenolate Sodium (Injectable Form)
5) By Leflunomide: Leflunomide Tablets (Oral), Leflunomide Injection
6) By Cyclophosphamide: Oral Cyclophosphamide, Injectable Cyclophosphamide
7) By Levothyroxine: Levothyroxine Sodium Tablets (Oral), Levothyroxine Sodium Injection
8) By Folic Acid: Folic Acid Supplements (Oral), Injectable Folic Acid
9) By Hydroxychloroquine: Hydroxychloroquine Tablets (Oral), Hydroxychloroquine Injectable Formulation
10) By Chloroquine: Chloroquine Tablets (Oral), Chloroquine Injectable Formulation
Pre-Book The Veterinary Autoimmune Disease Therapeutics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Veterinary Autoimmune Disease Therapeutics Market?
The predominant players in the veterinary autoimmune disease therapeutics market, such as RenBiologics, are dedicating their efforts towards the creation of technologically sophisticated solutions tailored to meet critical industry needs. The specialty of RenBiologics is the development of innovative treatments for kidney ailments and chronic disorders with a concentrated focus on biologics and regenerative medicine. The goal is to enhance results in areas like renal function and augment transplant success rates. To illustrate, Biocytogen, a biotech firm based in China, introduced a new subsidiary, RenBiologics, in January 2024 to concentrate on out-licensing fully human antibodies ripe for therapeutic development. This step is designed to utilize Biocytogen's vast collection of over 400,000 fully human antibody sequences, produced via its own RenMice platforms. RenBiologics is slated to establish collaborations with pharma and biotech firms for co-development and licensing of said antibodies, thereby increasing the potential for innovative antibody-based treatments. This launching serves to underline Biocytogen's pledge to solidify its position as a worldwide authority in antibody detection. The aim being the acceleration of the creation of innovative treatments across multiple therapeutic disciplines.
Who Are the Key Players In The Veterinary Autoimmune Disease Therapeutics Market?
Major companies operating in the veterinary autoimmune disease therapeutics market are:
• Pfizer Inc
• Merck & Co Inc
• AbbVie Inc.
• Sanofi S.A.
• Novartis AG
• GlaxoSmithKline
• Takeda Pharmaceutical Company
• Amgen Inc.
• Teva Pharmaceuticals Industries Ltd.
• Zoetis Inc
• Boehringer Ingelheim International GmbH
• Sumitomo Pharma Co. Ltd.
• IDEXX Laboratories Inc.
• Cipla Inc.
• Mallinckrodt Pharmaceuticals
• Virbac S.A
• Dechra Pharmaceuticals plc
• Neogen Corporation
• Vetoquinol S.A.
• Norbrook Laboratories Limited
• Heska Corporation
• Bimeda Holdings PLC
• Bayer Animal Health Inc
• Aratana Therapeutics Inc
• Hester Biosciences Limited
What Is The Most Dominant Region In The Veterinary Autoimmune Disease Therapeutics Market?
North America was the largest region in the veterinary autoimmune disease therapeutics market in 2023. The regions covered in the veterinary autoimmune disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
